TARS
NASDAQ
US
Tarsus Pharmaceuticals, Inc. - Common Stock
$70.12
▼ $-0.10
(-0.14%)
Vol 371K
6
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$3.5B
ROE
-26.3%
Margin
-22.2%
D/E
21.57
Beta
0.59
52W
$39–$85
Wall Street Consensus
15 analysts · Apr 20267
Strong Buy
7
Buy
1
Hold
0
Sell
0
Strong Sell
93.3%
Buy Rating
Price Chart
Similar Stocks
CRNX
Crinetics Pharmaceuticals Inc
$4.4B
INDV
Indivior Pharmaceuticals, Inc
P/E 35.8
$4.5B
GPCR
Structure Therapeutics Inc
$4.2B
EWTX
Edgewise Therapeutics Inc
$2.6B
LQDA
Liquidia Corp
$3.0B
SUPN
Supernus Pharmaceuticals Inc
$2.8B
ALMS
Alumis Inc
$1.0B
AMRX
Amneal Pharmaceuticals Inc
P/E 671.4
$4.0B
Earnings
Beat rate: 50.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.10 | $-0.20 | $-0.10 |
| Sep 2025 | $-0.36 | $-0.30 | +$0.06 |
| Jun 2025 | $-0.41 | $-0.48 | $-0.07 |
| Mar 2025 | $-0.75 | $-0.64 | +$0.11 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -32.4% | -32.4% | -32.4% | -32.4% | -26.3% | -26.3% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -19.8% | -31.1% | -31.1% | -31.1% | -22.2% | -22.2% |
| Gross Margin | 93.9% | 93.4% | 93.4% | 93.4% | 93.3% | 93.3% |
| D/E Ratio | 21.69 | 21.69 | 21.69 | 21.69 | 21.57 | 21.57 |
| Current Ratio | 5.26 | 5.26 | 5.26 | 5.26 | 4.29 | 4.29 |
Key Ratios
ROA (TTM)
-17.0%
P/S (TTM)
9.49
P/B
9.4
EPS (TTM)
$-2.01
CF/Share
$-3.86
Rev Growth 3Y
+47.5%
52W High
$85.25
52W Low
$38.51
$38.51
52-Week Range
$85.25
How does TARS compare to Pharmaceuticals peers?
Peer group: Mid-cap Pharmaceuticals ($2B+) · 25 companies
TARS valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(30.7)
vs Peers
vs Industry
Fair value
P/S ratio
9.5
▲
41%
above
peers
(6.7)
vs Peers
vs Industry
Pricier
P/B ratio
9.4
▲
81%
above
peers
(5.2)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(3.1%)
vs Peers
vs Industry
Low yield
TARS profitability vs Pharmaceuticals peers
ROE
-26.3%
▼
1%
below
peers
(-26.1%)
vs Peers
vs Industry
In line
Net margin
-22.2%
▼
1429%
below
peers
(-1.5%)
vs Peers
vs Industry
Weak
Gross margin
93.3%
▲
5%
above
peers
(88.9%)
vs Peers
vs Industry
In line
ROA
-17.0%
▼
80%
below
peers
(-9.5%)
vs Peers
vs Industry
Below avg
TARS financial health vs Pharmaceuticals peers
D/E ratio
21.6
▼
21%
below
peers
(27.4)
vs Peers
vs Industry
Above avg
Current ratio
4.3
▲
23%
above
peers
(3.5)
vs Peers
vs Industry
Below avg
Beta
0.6
▲
0%
above
peers
(0.6)
vs Peers
vs Industry
Less volatile
TARS fundamentals radar
TARS
Peer median
Industry
TARS profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
TARS vs peers: key metrics
Latest News
No related news yet